drugset
drugset / Trial / NCT04301310

Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants

NCT04301310 ↗

Phase 1 Withdrawn Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the effect of rifampin on the drug levels in blood and safety of BMS-986235, when taken by healthy participants.

Timeline

Start
2020-03-09
Primary completion
2020-03-16
Completion
2020-03-16

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed”

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986235 Small molecule — —
Subject Rifampicin Small molecule — —

Indications

No indication recorded.